Gilead Sciences Inc. (GILD) Short Interest Update
Gilead Sciences Inc. (NASDAQ:GILD) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 14,451,514 shares, a drop of 10.4% from the August 31st total of 16,127,731 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average trading volume of 9,601,218 shares, the short-interest ratio is currently 1.5 days.
Gilead Sciences (NASDAQ:GILD) opened at 78.97 on Thursday. Gilead Sciences has a 12-month low of $76.67 and a 12-month high of $111.11. The company has a 50-day moving average price of $79.44 and a 200-day moving average price of $85.67. The stock has a market capitalization of $104.21 billion, a PE ratio of 6.93 and a beta of 1.06.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. During the same period last year, the business posted $3.15 earnings per share. The firm’s revenue was down 5.7% compared to the same quarter last year. Analysts expect that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 16.56%.
In other Gilead Sciences news, Chairman John C. Martin sold 100,000 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the transaction, the chairman now directly owns 4,119,727 shares in the company, valued at $349,064,468.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John F. Milligan sold 112,000 shares of the stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in GILD. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock worth $2,220,410,000 after buying an additional 1,023,299 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Gilead Sciences by 2.6% in the second quarter. BlackRock Fund Advisors now owns 24,369,287 shares of the biopharmaceutical company’s stock worth $2,032,886,000 after buying an additional 612,544 shares in the last quarter. Capital World Investors raised its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Temasek Holdings Private Ltd raised its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock worth $1,113,383,000 after buying an additional 1,942,138 shares in the last quarter. 77.94% of the stock is currently owned by institutional investors and hedge funds.
GILD has been the topic of a number of recent research reports. Gabelli began coverage on shares of Gilead Sciences in a research report on Wednesday, June 1st. They set a “buy” rating and a $109.00 price target on the stock. Robert W. Baird restated an “outperform” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Monday, June 6th. Morgan Stanley restated a “hold” rating on shares of Gilead Sciences in a report on Monday, June 6th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, June 8th. Finally, Leerink Swann restated a “buy” rating and issued a $120.00 target price (down previously from $123.00) on shares of Gilead Sciences in a report on Thursday, June 9th. Eleven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $104.34.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.